Literature DB >> 8394671

Analysis of calcium-dependent protein kinase-C isoenzymes in intrinsically resistant cloned lines of LoVo cells: reversal of resistance by kinase inhibitor 1-(5-isoquinolinylsulfonyl) 2-methylpiperazine.

E Dolfini1, T Dasdia, G Perletti, M Romagnoni, F Piccinini.   

Abstract

In order to investigate the involvement of Protein Kinase C (PKC) in the signal transduction mechanisms related to intrinsic chemoresistance, two cellular clones were isolated from LoVo/WT colon adenocarcinoma cell line and their cytogenetic pattern was studied: LoVo C1.7 was intrinsically resistant to Doxorubicin while LoVo C1.5 showed the same resistance index as the mixed parental cell population. Two PKC isoforms, immunologically identified as beta and alpha PKC, were isolated from the cytosolic fraction of all cell types and one single peak of alpha PKC was obtained from the particulate fraction. Resistant LoVo C1.7 cells showed a significant increase of PKC activity; preincubation with H-7 induced PKC inhibition and reversal of drug resistance. These data suggest that in our cell system the identified calcium-dependent PKC subtypes can play a role in the mechanisms of intrinsic resistance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394671

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Protein kinases and multidrug resistance.

Authors:  M G Rumsby; L Drew; J R Warr
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 2.  Studies on low-level MDR cells.

Authors:  G Belvedere; E Dolfini
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 3.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin.

Authors:  E Dolfini; T Dasdia; G Arancia; A Molinari; A Calcabrini; R J Scheper; M J Flens; M B Gariboldi; E Monti
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin.

Authors:  G Conforti; A M Codegoni; E Scanziani; E Dolfini; T Dasdia; M Calza; M Caniatti; M Broggini
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

6.  Deciphering cellular states of innate tumor drug responses.

Authors:  Esther Graudens; Virginie Boulanger; Cindy Mollard; Régine Mariage-Samson; Xavier Barlet; Guilaine Grémy; Christine Couillault; Malika Lajémi; Dominique Piatier-Tonneau; Patrick Zaborski; Eric Eveno; Charles Auffray; Sandrine Imbeaud
Journal:  Genome Biol       Date:  2006-03-15       Impact factor: 13.583

7.  Inhibition of protein kinase C-alpha isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure.

Authors:  C A La Porta; E Dolfini; R Comolli
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.